Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr
Links:
Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Ear…
https://acrabstracts.org/abstract/subcutaneous-abatacept-vs-adalimumab-head-to-…
19-11-2024